No Widgets found in the Sidebar
Arthritis Z

SinoMab’s Phase III RA therapy trial meets primary endpoint

, , , , , , , ,

 

Click Here to Find Arthritis Pain Products 

​SinoMab BioScience has reported that its Phase III trial of SM03 to treat rheumatoid arthritis (RA) in China met the primary endpoint. 

SinoMab BioScience has reported that its Phase III trial of SM03 to treat rheumatoid arthritis (RA) in China met the primary endpoint.

 

Read More 

Related Post

21 Best CBD Cream for Arthritic Hands in 2023 | Discover Magazine

21 Best CBD Cream for Arthritic Hands in 2023 | Discover Magazine

Polyarticular Juvenile Idiopathic Arthritis Drug Market Research Report 2023-2031 …